Thomas Klag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Klag has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Jan Wehkamp
Department of Internal Medicine I, University of Tübingen, Tübingen, Germany
6 shared publications Jan Wehkamp
Division of Gastroenterology, Hepatology, Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
5 shared publicationsNisar P. Malek
Department of Internal Medicine I (Gastroenterology, Hepatology, Infectious Diseases), University Hospital Tübingen, Tübingen, Germany
5 shared publicationsMartin Goetz
Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany
4 shared publications- Claudius Falch
Department of Surgery and Transplantation, University of Tuebingen, Hoppe-Seyler-Strasse 3, 72076, Tuebingen, Germany.
2 shared publications - Eduard Friedrich Stange
Innere Medizin I, Universitätsklinikum Tübingen, Tübingen, Deutschland
2 shared publications
Latest Publications
- Open Access
- 30 January 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (1) , 45-52
Quality of life in inflammatory bowel diseases: it is not all about the bowel
Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life, and the quality of life (QUOL) interacts with disease activity, improving QUOL should be one of the main goals of therapy. This study aims to identify factors contributing to good or impaired QUOL.Methods: Questionnaires addressing health-related QUOL and other psychological and social features were positioned on our institutions’ webpage and on the webpage of the largest self-help group for IBD in Germany. Patients were subdivided according to their QUOL score with a cutoff of <60. We used the Short Inflammatory Bowel Disease Questionnaire, the Assessment of the Demand for Additional Psychological Treatment, and the Fear of Progression Questionnaire Short Form.Results: High numbers of patients in both subgroups showed an impaired QUOL (87.34% in UC, 91.08% in CD). Active extraintestinal manifestations, smoking, high fear of progression and high demand for psychotherapy were associated with reduced QUOL. In addition, polypharmacological interventions did not result in a good QUOL, but ostomies are linked to improved QUOL especially in CD patients.Conclusions: Scores used in clinical day-to-day-practice mainly focusing on somatic factors do not sufficiently address important aspects concerning QUOL. Most importantly, extraintestinal manifestations show a hitherto underestimated impact on QUOL.
- 30 January 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (1) , 45-52
Open AccessQuality of life in inflammatory bowel diseases: it is not all about the bowel
Background/Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life, and the quality of life (QUOL) interacts with disease activity, improving QUOL should be one of the main goals of therapy. This study aims to identify factors contributing to good or impaired QUOL.Methods: Questionnaires addressing health-related QUOL and other psychological and social features were positioned on our institutions’ webpage and on the webpage of the largest self-help group for IBD in Germany. Patients were subdivided according to their QUOL score with a cutoff of <60. We used the Short Inflammatory Bowel Disease Questionnaire, the Assessment of the Demand for Additional Psychological Treatment, and the Fear of Progression Questionnaire Short Form.Results: High numbers of patients in both subgroups showed an impaired QUOL (87.34% in UC, 91.08% in CD). Active extraintestinal manifestations, smoking, high fear of progression and high demand for psychotherapy were associated with reduced QUOL. In addition, polypharmacological interventions did not result in a good QUOL, but ostomies are linked to improved QUOL especially in CD patients.Conclusions: Scores used in clinical day-to-day-practice mainly focusing on somatic factors do not sufficiently address important aspects concerning QUOL. Most importantly, extraintestinal manifestations show a hitherto underestimated impact on QUOL.
- 4 February 2020
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 58 (03) , 224-233
Infodemiology of Crohn’s disease and Ulcerative colitis using Google Trends – an approach to investigate patient needs
Introduction Inflammatory bowel diseases (IBD) highly affect quality of life. The course of disease and success of treatment are variable. These factors result in a high number of psychiatric comorbidities with patients requiring extensive medical consultation or additional psychotherapy. Unfortunately, time is often limited in daily clinical care, which leaves patients not feeling sufficiently informed about their disease. Patients often compensate by searching the internet, with possibly harmful information. We aim to identify information gaps to allow a more complete education of patients. Methods We analyzed the internet search behavior using the key words [Morbus Crohn] (CD) and [Colitis ulcerosa] (UC) using Google Trends. In addition, we investigated which websites are the first hits on Google, as those are most likely visited by patients. Results Symptoms, nutrition and therapy are central topics for persons interested in IBD. The searches concerning symptoms or therapies do not match the actual incidence or prevalence of comorbidities as well as the more commonly used therapies or established nutritional recommendations. We found a distinct impact of well-known personalities on disease related searches. The first suggested websites on google showed great heterogeneity of responsible publishers, often with possible conflict of interests. In line with those observations, quality of website content is highly heterogeneous. Conclusion This study showed a need of information concerning symptoms, nutrition and therapy that should be considered during patient education. Since time in physician patient dialogue is short it may be helpful to further evaluate websites independently in order to give recommendations of websites offering reliable information.
- 4 February 2020
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 58 (03) , 224-233
Infodemiology of Crohn’s disease and Ulcerative colitis using Google Trends – an approach to investigate patient needs
Introduction Inflammatory bowel diseases (IBD) highly affect quality of life. The course of disease and success of treatment are variable. These factors result in a high number of psychiatric comorbidities with patients requiring extensive medical consultation or additional psychotherapy. Unfortunately, time is often limited in daily clinical care, which leaves patients not feeling sufficiently informed about their disease. Patients often compensate by searching the internet, with possibly harmful information. We aim to identify information gaps to allow a more complete education of patients. Methods We analyzed the internet search behavior using the key words [Morbus Crohn] (CD) and [Colitis ulcerosa] (UC) using Google Trends. In addition, we investigated which websites are the first hits on Google, as those are most likely visited by patients. Results Symptoms, nutrition and therapy are central topics for persons interested in IBD. The searches concerning symptoms or therapies do not match the actual incidence or prevalence of comorbidities as well as the more commonly used therapies or established nutritional recommendations. We found a distinct impact of well-known personalities on disease related searches. The first suggested websites on google showed great heterogeneity of responsible publishers, often with possible conflict of interests. In line with those observations, quality of website content is highly heterogeneous. Conclusion This study showed a need of information concerning symptoms, nutrition and therapy that should be considered during patient education. Since time in physician patient dialogue is short it may be helpful to further evaluate websites independently in order to give recommendations of websites offering reliable information.
- Open Access
- 30 July 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (3) , 340-348
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Ustekinumab is effective in active Crohn's disease. In a retrospective study we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average "real world" patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes. Forty-one patients with mild to severe active Crohn's disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn's Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed. The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies. Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort.
- 30 July 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (3) , 340-348
Open AccessUstekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
Ustekinumab is effective in active Crohn's disease. In a retrospective study we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average "real world" patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes. Forty-one patients with mild to severe active Crohn's disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn's Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed. The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies. Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort.
- 1 July 2019
- Published by Georg Thieme Verlag KG in Der Klinikarzt
- Vol. 48 (07) , 301-307
Mikrobiom und chronisch-entzündliche Darmerkrankungen
ZUSAMMENFASSUNG: Die Pathogenese chronisch-entzündlicher Darmerkrankungen ist durch genetische und Umweltfaktoren beeinflusst. Das Mikrobiom als Umweltfaktor der Darmbarriere steht zunehmend im Interesse der Forschung. Dieses Mikrobiom kann dabei nicht als eigenes Organsystem betrachtet werden, sondern wird durch die unspezifische Immunantwort des Darmepithels moduliert und gesteuert. Primäre und sekundäre Änderungen des Mikrobioms gehen fließend ineinander über und haben mögliche pathophysiologische und therapeutische Implikationen.
- 1 July 2019
- Published by Georg Thieme Verlag KG in Der Klinikarzt
- Vol. 48 (07) , 301-307
Mikrobiom und chronisch-entzündliche Darmerkrankungen
ZUSAMMENFASSUNG: Die Pathogenese chronisch-entzündlicher Darmerkrankungen ist durch genetische und Umweltfaktoren beeinflusst. Das Mikrobiom als Umweltfaktor der Darmbarriere steht zunehmend im Interesse der Forschung. Dieses Mikrobiom kann dabei nicht als eigenes Organsystem betrachtet werden, sondern wird durch die unspezifische Immunantwort des Darmepithels moduliert und gesteuert. Primäre und sekundäre Änderungen des Mikrobioms gehen fließend ineinander über und haben mögliche pathophysiologische und therapeutische Implikationen.
- 16 February 2019
- Published by Springer Nature in Gastro-News
- Vol. 6 (1) , 26-37
Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED
- 16 February 2019
- Published by Springer Nature in Gastro-News
- Vol. 6 (1) , 26-37
Wirkmechanismen und Wirkung von Biologika und JAK-Inhibitoren bei CED
- 29 November 2018
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 34 (2) , 369-373
Enterocutaneous fistula in severely active Crohn’s disease: preoperative anti-TNF alpha treatment to limit bowel resection—report of a case
Strategies for limiting the extent of bowel resection in cases of enterocutaneous or interenteric fistulas in severely active Crohn’s disease are urgently necessary. Anti-inflammatory therapy with tumor necrosis factor alpha (anti-TNF alpha) inhibitors has positive impact on fistulizing Crohn’s disease. We describe a case of a 32-year-old male suffering from enterocutaneous fistula in severely active Crohn’s disease.
- 29 November 2018
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 34 (2) , 369-373
Enterocutaneous fistula in severely active Crohn’s disease: preoperative anti-TNF alpha treatment to limit bowel resection—report of a case
Strategies for limiting the extent of bowel resection in cases of enterocutaneous or interenteric fistulas in severely active Crohn’s disease are urgently necessary. Anti-inflammatory therapy with tumor necrosis factor alpha (anti-TNF alpha) inhibitors has positive impact on fistulizing Crohn’s disease. We describe a case of a 32-year-old male suffering from enterocutaneous fistula in severely active Crohn’s disease.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1241 - Clinical Experience with Ustekinumab in Selected Crohns Disease Patients
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1241 - Clinical Experience with Ustekinumab in Selected Crohns Disease Patients
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S985
Human Endogenous Retroviruses and Residues of Ancient Times - are Differentially Expressed in Crohǹs Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S985
Human Endogenous Retroviruses and Residues of Ancient Times - are Differentially Expressed in Crohǹs Disease
- 13 February 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 55 (02) , 149-152
Low-grade appendiceal mucinous neoplasm (LAMN) – 3-year endoscopic follow-up underlines benign course of LAMN type 1
Low-grade appendiceal mucinous neoplasms (LAMNs) are neoplastic lesions with potential progression to pseudomyxoma peritonei (PMP). In most cases, diagnosis is made because of suspected acute appendicitis or incidentally by computed tomography (CT). However, incidental diagnosis during colonoscopy is rare. We present the case of a 63-year-old man with a LAMN type 1 lesion, diagnosed at routine colonoscopy for surveillance of ulcerative colitis. Because in earlier surveillance colonoscopies, this lesion was misinterpreted as fecal polution, for the first time, this case describes retrospectively a 3-year endoscopic follow-up of LAMN type 1, underlining the benign course of these kind of lesions compared to type 2 lesions with submucosal infiltration. Even though endoscopy and sonography are not accepted as method of choice to detect LAMN lesions, our case highlights their role regarding diagnosis of small lesions, as CT scan was not able to detect the lesion in our case. Even though LAMNs are rare, awareness of LAMN lesions in routine colonoscopy is favorable as potential progression to PMP can not be ruled out. Niedriggradige muzinöse Neoplasien der Appendix vermiformis sind neoplastische Läsionen mit dem potenziellen Risiko zur Progression zu einem Pseudomyxoma peritonei. Meist wird die Diagnose im Rahmen einer vermuteten akuten Appendizitis oder zufällig in der Computertomografie (CT) gestellt. Wir präsentieren hier den Fall eines 63-jährigen Patienten mit einer LAMN-Typ-1-Läsion, welche bei einer jährlichen Routinekoloskopie bei Colitis ulcerosa diagnostiziert wurde. Unser Fallbericht dokumentiert erstmalig einen 3-Jahres-Verlauf einer LAMN-Typ-1-Läsion, da in vorherigen Koloskopien diese Läsion als Stuhlverschmutzung fehlinterpretiert wurde. Somit unterstützt dieser Fallbericht die Annahme, dass solche Läsionen meist einen benignen Verlauf nehmen, im Gegensatz zu LAMN-Typ-2-Läsionen mit Infiltration der Submukosa. Obwohl die Computertomografie die diagnostische Modalität der Wahl darstellt, scheint dies nicht der Fall für kleine Läsionen, wie in diesem Fallbericht zu sein. Hier scheinen die gründliche Koloskopie sowie möglicherweise die Sonografie überlegen zu sein, wenngleich auch hier der Blick des erfahrenen Untersuchers erforderlich ist. Selbst wenn LAMN-Läsionen selten sind, sollten sie als endoskopische/sonografische Differentialdiagnose bedacht werden.
- 13 February 2017
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 55 (02) , 149-152
Low-grade appendiceal mucinous neoplasm (LAMN) – 3-year endoscopic follow-up underlines benign course of LAMN type 1
Low-grade appendiceal mucinous neoplasms (LAMNs) are neoplastic lesions with potential progression to pseudomyxoma peritonei (PMP). In most cases, diagnosis is made because of suspected acute appendicitis or incidentally by computed tomography (CT). However, incidental diagnosis during colonoscopy is rare. We present the case of a 63-year-old man with a LAMN type 1 lesion, diagnosed at routine colonoscopy for surveillance of ulcerative colitis. Because in earlier surveillance colonoscopies, this lesion was misinterpreted as fecal polution, for the first time, this case describes retrospectively a 3-year endoscopic follow-up of LAMN type 1, underlining the benign course of these kind of lesions compared to type 2 lesions with submucosal infiltration. Even though endoscopy and sonography are not accepted as method of choice to detect LAMN lesions, our case highlights their role regarding diagnosis of small lesions, as CT scan was not able to detect the lesion in our case. Even though LAMNs are rare, awareness of LAMN lesions in routine colonoscopy is favorable as potential progression to PMP can not be ruled out. Niedriggradige muzinöse Neoplasien der Appendix vermiformis sind neoplastische Läsionen mit dem potenziellen Risiko zur Progression zu einem Pseudomyxoma peritonei. Meist wird die Diagnose im Rahmen einer vermuteten akuten Appendizitis oder zufällig in der Computertomografie (CT) gestellt. Wir präsentieren hier den Fall eines 63-jährigen Patienten mit einer LAMN-Typ-1-Läsion, welche bei einer jährlichen Routinekoloskopie bei Colitis ulcerosa diagnostiziert wurde. Unser Fallbericht dokumentiert erstmalig einen 3-Jahres-Verlauf einer LAMN-Typ-1-Läsion, da in vorherigen Koloskopien diese Läsion als Stuhlverschmutzung fehlinterpretiert wurde. Somit unterstützt dieser Fallbericht die Annahme, dass solche Läsionen meist einen benignen Verlauf nehmen, im Gegensatz zu LAMN-Typ-2-Läsionen mit Infiltration der Submukosa. Obwohl die Computertomografie die diagnostische Modalität der Wahl darstellt, scheint dies nicht der Fall für kleine Läsionen, wie in diesem Fallbericht zu sein. Hier scheinen die gründliche Koloskopie sowie möglicherweise die Sonografie überlegen zu sein, wenngleich auch hier der Blick des erfahrenen Untersuchers erforderlich ist. Selbst wenn LAMN-Läsionen selten sind, sollten sie als endoskopische/sonografische Differentialdiagnose bedacht werden.